Lookup NU author(s): Dr Vijay Kunadian
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
Author(s): Navarese EP, Buffon A, Kozinski M, Obonska K, Rychter M, Kunadian V, Austin D, De Servi S, Sukiennik A, Kubica J
Publication type: Review
Publication status: Published
Journal: QJM: An International Journal of Medicine
Print publication date: 01/02/2013
ISSN (print): 1460-2725
Publisher: OXFORD UNIV PRESS